Maintenance Therapy

Core Conclusion

Initiating oral lenalidomide maintenance (10 to 15 mg daily for 21 of 28 days) after induction or transplant prolongs median progression-free survival by 20 to 30 months and reduces disease progression risk by over 50%.

Detailed Points

• (1) The Goal of Maintenance (Keeping the Disease Asleep): Because multiple myeloma is not yet curable, tiny, undetectable amounts of myeloma cells can remain in your body even after a complete response. The goal of maintenance therapy is to act as a long-term guardian. It uses lighter, continuous therapy to suppress any leftover cells, prolong your remission, delay the return of the disease, and ultimately improve your overall survival.
• (2) Standard of Care Drugs and Typical Duration: For the vast majority of patients, a daily oral immunomodulatory pill called Lenalidomide (Revlimid) is the standard of care for maintenance.

  • Duration: Currently, clinical guidelines and standard practice in the U.S. recommend taking maintenance therapy continuously until the disease progresses or the side effects become intolerable. Large trials have shown that staying on the medication provides the best survival benefits. However, if you achieve a very deep, sustained response, you and your doctor may discuss enrolling in a clinical trial that is evaluating whether it is safe to stop treatment after a fixed number of years.
• (3) Differences in Strategies (Standard-Risk vs. High-Risk): Your medical team will tailor your maintenance plan based on the genetic "fingerprint" of your myeloma:

  • Standard-Risk: If your myeloma does not have aggressive genetic markers, you will typically receive a single drug (Lenalidomide monotherapy).
  • High-Risk: If your myeloma features high-risk genetics, keeping the disease controlled is an urgent priority. Your doctor may start your maintenance earlier—around 60 days after a stem cell transplant—and will highly recommend a "doublet" (two-drug) regimen. This usually involves combining Lenalidomide with a proteasome inhibitor like Bortezomib (Velcade) or an anti-CD38 monoclonal antibody like Daratumumab to aggressively prevent an early relapse.
• (4) Important Side Effects to Monitor: While maintenance therapy is designed to be gentler than your initial chemotherapy, it does carry risks that your doctor will monitor closely:

  • Blood Counts: Lenalidomide can suppress your bone marrow. In clinical trials, severe neutropenia (low white blood cells) occurred in 50% of patients on Lenalidomide maintenance compared to just 18% on placebo, and thrombocytopenia (low platelets) occurred in 15% versus 5%. Your doctor will check your blood regularly to prevent infections.
  • Secondary Cancers: There is a slightly increased risk of developing a second primary cancer (such as a skin or blood cancer) while on Lenalidomide maintenance—occurring in about 14% of patients compared to 4% of patients on a placebo. This risk is notably present when used after high-dose Melphalan (transplant).

Please be assured that your doctor will carefully weigh these risks against the proven, significant survival benefits of maintenance therapy. Always promptly report any new side effects so your team can safely adjust your doses and keep you feeling your best.

The above content is sourced from the following references

• Patient Handbook (International Myeloma Foundation)
• First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma
• Multiple Myeloma Research Foundation Patient Toolkit
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma